Fragment-Based Drug Discovery (FBDD) Using the diSPR™ Technique on Pioneer Systems with OneStep^® and NeXtStep™ Injection Methodologies

The detection and characterization of fragment binding events is facilitated by sensitive biophysical technologies, capable of detecting low affinity interactions of low molecular weight compounds. Over the last decade approaches such as nuclear magnetic resonance (NMR), X-ray crystallography, differential scanning fluorimetry (DSF), and surface plasmon resonance (SPR) have become core technologies in many pharma and biotech settings for the identification of these low-affinity fragment compounds. This application note describes how the dynamic injection SPR (diSPR) technique, marks a quantum innovation in characterizing molecular interactions.